drugset / Trial / NCT06774144
Rezafungin Prophylaxis in Liver Transplant
Phase 3
Enrolling by invitation
385 enrolled
Fernanda P Silveira, MD, MS
Melinta Therapeutics, Inc. · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This is an interventional study to evaluate the efficacy of rezafungin, a new echinocandin, for the prevention of invasive fungal infections (IFIs) after liver transplantation. Patients who receive rezafungin will be compared to a similar group of patients who underwent liver transplantation in the preceding two years for the incidence of IFIs.
Timeline
- Start
- 2025-10-15
- Primary completion
- 2028-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rezafungin | Other / unclassified | 200 mg | Intravenous |
| Comparator | Fluconazole | Small molecule | — | — |
| Comparator | Voriconazole | Small molecule | — | — |